Meloflam

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Meloflam

Quick Facts

Property Description
Active ingredient Meloxicam (INN)
Form Tablet, Oral Suspension, Solution for Injection
Pharmacological class Nonsteroidal Anti-Inflammatory Drug (NSAID)
Core Action Analgesic, Anti-inflammatory, Antipyretic
Origin Synthetic (Oxicam derivative)

What Type of Medicine is Meloflam (Meloxicam)?

Meloflam is a pharmaceutical product primarily containing the prescription-only active ingredient Meloxicam, which is classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID). Its structure places it within the specialized Oxicam subclass, distinguishing it as an enolic acid derivative. Meloxicam is an NSAID indicated for the relief of inflammatory signs and symptoms. This indicates the medicine’s primary role is to manage physical discomfort and swelling. Pharmacological studies support its recognized action as a COX-2 preferential inhibitor, making it a well-established therapeutic agent in its class.

Composition and Forms of Meloflam

The medicine's composition is based on the single active ingredient, Meloxicam, combined with the pharmaceutical excipients necessary for stability and proper absorption. Meloxicam is available in various preparations, including oral tablets, a liquid oral suspension, and a solution for injection. This diversity in pharmaceutical forms is clinically recognized for facilitating different administrative routes (oral, parenteral, rectal), ensuring the drug can be delivered optimally depending on the patient's condition. The development of these forms reflects the medical commitment to providing flexible administration options for this established substance.

The Core Purpose of Meloflam: Anti-inflammatory and Analgesic Action

The fundamental function of Meloflam is to provide relief from the core symptoms associated with inflammation, such as chronic pain and stiffness. Meloxicam achieves this by acting to moderate the inflammatory cascade. Meloxicam works by stopping the body's production of substances that cause pain and inflammation. Its primary action is to exert analgesic (pain-relieving), anti-inflammatory (swelling-reducing), and antipyretic (fever-reducing) effects, which are generally used to mitigate the physical discomfort arising from underlying inflammatory processes. This makes it a standard option for conditions where relief from pain and inflammation is paramount.

Regulatory References

  1. Nonsteroidal Anti-Inflammatory Drug (NSAID)
  2. COX-2 preferential inhibitor
  3. DailyMed on Meloxicam
  4. analgesic
  5. anti-inflammatory

What side effects are possible with Meloflam?

Safety Warnings and Adverse Reactions

Meloflam is associated with a risk of serious cardiovascular (CV) thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with the duration of use and is a prominent regulatory warning.

Serious Adverse Reactions

Additionally, the medication carries a risk of serious gastrointestinal (GI) adverse events, including bleeding, ulceration, and perforation of the stomach or intestines, which may be fatal and can occur without warning. Other documented serious reactions include hepatotoxicity (liver damage), renal toxicity (kidney damage, acute renal failure), hypertension, heart failure/edema, and severe hypersensitivity reactions (e.g., Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, anaphylaxis, and DRESS).

Common Adverse Reactions

Adverse reactions most frequently reported in clinical studies involve the gastrointestinal system and include diarrhea, dyspepsia (indigestion), nausea, abdominal pain, and flatulence. Other common effects include dizziness and headache.

Population-Specific Safety Considerations

Elderly patients are at greater risk for serious GI adverse events. Use of Meloflam in late pregnancy (30 weeks gestation and later) is contraindicated due to the risk of premature closure of the fetal ductus arteriosus. Use in patients with a history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs is contraindicated, as is use for peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Overdose and Emergency Response

Meloflam Overdose and when to seek help — Official Regulatory Information

The Meloflam (Meloxicam) overdose profile is strictly based on symptoms and required actions documented in regulatory prescribing information. Acute overexposure may initially present with common gastrointestinal and neurological manifestations.

Documented Overdose Manifestations

Common presentations include epigastric pain, nausea, vomiting, lethargy, and drowsiness. Gastrointestinal bleeding may also occur following acute NSAID overdose. Elderly patients are considered at greater risk for serious gastrointestinal adverse events, which are complications of overdose.

Severe and Life-Threatening Outcomes

Severe poisoning is associated with critical systemic effects that require urgent intervention. These manifestations include cardiovascular collapse, cardiac arrest, hypertension, coma, convulsions, respiratory depression, and acute organ damage such as acute renal failure and hepatic dysfunction. Anaphylactoid reactions have also been reported with NSAID overexposure.

When to Seek Immediate Medical Help

Patients must seek immediate emergency help if signs of severe poisoning, such as loss of consciousness or cardiovascular effects, are observed. Urgent medical care is also mandated if a hypersensitivity reaction, such as an anaphylactoid reaction, occurs.

Management Notes

No specific antidote for Meloxicam is known. Management is primarily symptomatic and supportive treatment. The administration of Cholestyramine is officially documented to accelerate the clearance of Meloxicam from the system.

Therapeutic Uses of Meloflam

What Meloflam Treats: Main Uses and Benefits

Meloflam (Meloxicam) is commonly used to help with the symptomatic relief of symptoms related to physical discomfort, stiffness, and swelling associated with conditions involving inflammatory processes. The medication is relevant for easing pain, tenderness, swelling, and stiffness associated with various forms of arthritis.

The medication is applicable in conditions characterized by periods of heightened symptoms, commonly used for the management of Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis in adults. It is also used in specific pediatric populations to treat the signs and symptoms of Juvenile Idiopathic Arthritis (JIA) in children aged 2 years and older. This supportive symptomatic assistance is commonly used for managing the cluster of inflammatory symptoms, offering relief that may assist with maintaining functional stability.

The medication is relevant for easing discomfort in situations where patients experience heightened symptoms:

“Meloflam provides supportive relief when symptoms interfere with routine activities.”

In clinical settings marked by increased discomfort, such as post-operative scenarios, Meloflam is commonly used to provide supportive symptomatic relief for skeletomuscular pain, helping to ease the overall symptom load during challenging, acute phases.


Quick Fact: Relief for Inflammatory Symptoms Meloflam is commonly used to manage symptoms related to inflammatory or irritative states that create noticeable physiological strain, primarily focusing on chronic joint pain and acute musculoskeletal discomfort.

Regulatory References

  1. NIH MedlinePlus overview on Meloxicam

Eligibility and Restrictions for Use

Who Can and Cannot Use Meloflam? — Official Regulatory Information

Regulatory documents define strict eligibility criteria for Meloflam (Meloxicam) based on medical history, physiological status, and age, with contraindications listed for high-risk populations.

Populations For Whom Use Is Contraindicated:

  • Patients with known hypersensitivity to meloxicam or any other NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), including those who have experienced asthma, hives, or allergic-type reactions after taking aspirin.
  • Patients who are undergoing or have recently undergone Coronary Artery Bypass Graft (CABG) surgery.
  • Women who are at 30 weeks gestation or later in pregnancy.
  • Patients with active gastrointestinal bleeding, ulceration, or perforation.
Age and Condition-Specific Eligibility Rules: Population Group Eligibility Status Key Restriction
Children under 2 years Use Not Established Safety and efficacy have not been established.
Children ge 2 years Eligible Approved for Juvenile Rheumatoid Arthritis; may be weight-restricted for some formulations.
Geriatric Patients Use with Caution Greater risk for GI, heart, and kidney issues; lowest effective dose for the shortest duration is advised.
Severe Heart Failure Avoid Use Avoid use unless benefits clearly outweigh the risk of worsening cardiac function.
Renal Impairment Restricted Contraindicated in non-dialyzed severe renal failure; maximum dose is limited to 7.5 mg/day for patients on chronic hemodialysis.

Use in pregnant women between 20 and 30 weeks gestation must be strictly limited due to fetal risks. The drug may be excreted in human milk, requiring caution during breastfeeding.

What should I know about interactions with other medicines?

Meloflam Interactions with other medicines and products

Official regulatory documents classify Meloflam (Meloxicam) interactions into several risk categories based on altered drug exposure or increased risk of adverse events with co-administration.

Formal Regulatory Restrictions

Meloflam is strictly contraindicated for the treatment of pain occurring immediately before or after Coronary Artery Bypass Graft (CABG) surgery. It is also prohibited in patients who have experienced allergic-type reactions (e.g., asthma, hives) after taking Aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs).

Interactions Altering Drug Levels

  • Lithium: Co-administration results in increased lithium plasma levels due to reduced renal clearance. Patients should be monitored for signs of toxicity.
  • Methotrexate: Meloxicam may increase methotrexate plasma levels, especially at higher doses, which can enhance its toxicity.
  • Cholestyramine: This agent significantly increases the clearance of Meloxicam, resulting in a reduction of the drug's overall plasma exposure.

Interactions Increasing Shared Risk

  • Anticoagulants (e.g., Warfarin), Oral Corticosteroids, SSRIs, and SNRIs when combined with Meloflam, increase the risk of serious bleeding complications and gastrointestinal events due to additive pharmacodynamic effects.
  • Co-administration with other NSAIDs (including analgesic doses of Aspirin) is not generally recommended due to the cumulative risk of gastrointestinal and renal adverse effects.

Interactions Impairing Drug Efficacy

  • Meloflam may diminish the antihypertensive effects of ACE-inhibitors and Angiotensin Receptor Blockers (ARBs), as well as reduce the diuretic effect of Diuretics.

Population-Specific Considerations

Co-administration with ACE-inhibitors or ARBs may result in a greater deterioration of renal function in specific populations, including the elderly and those with volume depletion.

Mechanism of Action

Preferential Modulation of COX Enzymes

Meloflam (Meloxicam) exerts its action through the inhibition of the Cyclooxygenase ( COX) enzyme. Its mechanism involves preferentially targeting the inducible COX-2 isoform over the constitutive COX-1. COX-2 is upregulated by inflammatory signals and drives the synthesis of prostanoids.

Blockade of Prostaglandin Synthesis Cascade

This preferential inhibition suppresses the biochemical pathway that converts Arachidonic Acid into lipid mediators, primarily Prostaglandin E2 ( PGE2). This blockage modifies early molecular steps that shape systemic physiological outcomes. The resulting physiological consequence is a reduction in the mediators that modulate nociceptor thresholds and contribute to local fluid exudation.

Dual Modulation of Pain and Temperature Signaling

Meloflam's mechanism engages both peripheral and central pathways. Peripherally, it dampens the PGE2-mediated sensitization of nociceptors. Centrally, it adjusts the hypothalamic mechanism that controls body temperature via PGE2 inhibition. This dual action modulates both central and peripheral prostaglandin-mediated signaling.

Dosage and Administration Information

How to Use Meloflam: Official Administration Guidelines

Meloflam (Meloxicam) is used according to specific, standardized instructions to ensure consistent administration. The medicine is primarily taken via the oral route, but a solution for intravenous (IV) injection is also an approved route for specific acute settings.

Approved Dosing and Frequency

Meloflam is administered once daily for all approved regimens. For adults managing conditions like Rheumatoid or Osteoarthritis, the usual starting dose is 7.5 mg once a day. This dose may be adjusted upward based on individual needs, but the total maximum recommended oral dose is 15 mg per day. For the management of acute moderate-to-severe pain, the intravenous regimen involves a 30 mg dose administered once daily.

Administration Conditions and Adjustments

Instruction Category Official Guideline
Timing in Relation to Meals May be taken with or without food.
Administration Method Oral tablets/capsules must be swallowed whole and should not be crushed. The oral suspension must be shaken gently before use.
Duration Principle The drug should be used at the lowest effective dose for the shortest duration consistent with treatment goals.

Dosage adjustments are specifically required for certain patient groups. For adults undergoing hemodialysis, the maximum daily oral dose is restricted to 7.5 mg. For pediatric patients with Juvenile Idiopathic Arthritis (JIA), the dose is calculated based on weight, not to exceed 7.5 mg daily. If a dose is missed, it is generally advised to take the next dose at the regularly scheduled time and to avoid doubling the dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase III Clinical Trials

Research explored the drug in relation to specific biological pathways.

Research describing the primary Phase III trials indicates they were double-blind, randomized, and placebo-controlled. The primary objective was to evaluate outcomes of administering the drug versus placebo in adult participants over a 12-week period.

  • Measures of Disease Activity: Studies evaluated changes in disease activity scores. The studies suggest that participants receiving the drug were observed to have lower mean disease activity scores compared to the placebo group at the 12-week endpoint. The trials also measured pain levels and joint swelling as secondary endpoints.
  • Long-Term Follow-Up: Open-label extensions of the Phase III trials studied changes in disease activity over a period of up to two years. Research has examined the measurement of overall quality of life metrics over the extended duration.

Special Population and Safety Studies

Studies in Hepatic Impairment

Research explored the drug's metabolism in patients with mild or severe liver impairment. Studies monitored drug concentration levels in these populations compared to concentrations observed in control groups of participants without hepatic impairment.

Combination Therapy Research

Research examined findings related to symptom control and long-term complications when the drug was studied alongside standard first-line treatments. Studies have compared the outcomes of the drug with alternative treatments, examining various endpoints.

Tolerability and Side Effects

Across all studies, the most commonly reported adverse events were headache, nausea, and injection site reactions. Study findings also reported that a smaller percentage of participants experienced mild respiratory infections. Study investigators monitored the frequency and severity of these adverse events. Studies also included measurement of specific laboratory markers, such as liver enzyme levels, and how frequently participants discontinued the drug due to adverse events.

Frequently Asked Questions (FAQ)

Common questions about Meloflam (FAQ)

Q: How long does Meloflam stay in your system after the last dose?

A: According to official product information, the medicine has an elimination half-life of approximately 15 to 20 hours. This is the time it takes for half of the drug to be cleared from the body. The half-life of the drug supports its indication for once-daily administration.

Q: Can I take Meloflam with common cold and flu medicines?

A: Meloflam should generally not be used at the same time as other nonsteroidal anti-inflammatory drugs (NSAIDs) because this increases the risk of side effects, particularly those affecting the stomach and kidneys. Official documents recommend caution regarding the concurrent use of Meloflam with other NSAIDs, as many cold and flu products may contain them. Checking product ingredients is consistent with minimizing interaction risk.

Q: Can I take an antacid like Tums while on Meloflam?

A: Official studies have indicated that taking common antacids does not significantly alter how Meloflam is absorbed into the body. This suggests that antacids are unlikely to significantly reduce the effectiveness of Meloflam.

Q: Can Meloflam cause stomach pain or heartburn, and what helps stop it?

A: Yes, common side effects reported in clinical studies include gastrointestinal issues such as stomach pain, indigestion, and nausea. Official product information, while listing these effects, does not provide specific guidance on over-the-counter remedies to treat them.

Q: What is the duration of pain relief I can expect from a single dose of Meloflam?

A: Meloflam is formulated and approved for once-daily administration. The drug is indicated for once-daily dosing, which reflects its long duration of action.

Q: Is Meloflam more effective for acute injuries or chronic conditions?

A: Meloflam is primarily indicated for the chronic management of symptoms associated with inflammatory conditions like osteoarthritis and rheumatoid arthritis. However, an injectable form of the drug is specifically approved for the short-term management of acute moderate to severe pain.

Q: Does Meloflam make you sleepy or affect your driving ability?

A: Official product labeling notes that Meloflam can cause side effects such as dizziness, drowsiness, and blurred vision. Caution is generally recommended when driving or operating machinery if side effects such as dizziness or drowsiness occur.

Q: Is Meloflam safe to take long-term for chronic joint pain?

A: Official regulatory warnings emphasize that the risk of serious cardiovascular events (like heart attack or stroke) and gastrointestinal problems (like bleeding or ulcers) may increase with the length of time Meloflam is used. Regulatory warnings emphasize the need to use the lowest effective dose for the shortest duration necessary, as risks may increase with the length of use.

Q: Is it normal to feel a bit dizzy the first few times I take Meloflam?

A: Dizziness is a commonly reported adverse reaction documented in clinical trials, suggesting it is a possibility at any time during therapy. Experiencing dizziness is a recognized possibility.

Q: Can you use Meloflam for headaches or migraines?

A: The single active ingredient in Meloflam is approved to treat inflammatory conditions like arthritis. There is a different, specific fixed-dose combination product containing the same active ingredient along with another medicine that is approved for the acute treatment of migraine headaches.

Q: Will Meloflam affect my ability to get pregnant or affect fertility?

A: Based on its mechanism of action, Meloflam may delay or prevent ovulation in women. Regulatory information advises that the medicine is not recommended for women who are actively trying to conceive. Additionally, animal studies suggest that the drug may compromise male fertility.

Q: How often do people report liver issues when taking Meloflam?

A: While serious liver damage is rare, official clinical trial data show that elevations in liver enzymes (markers of liver stress) greater than three times the upper limit of normal have been reported in up to 15% of patients, with marked increases observed in about 1%.

Q: Is there a maximum number of days or weeks Meloflam is usually prescribed for?

A: The official guidance for Meloflam administration stresses the importance of using the drug for the shortest possible duration that is consistent with the patient’s treatment goals. There is no set maximum period, but the risk of serious side effects increases with the length of use.

Q: Can Meloflam cause a rash or other skin reactions?

A: Yes, Meloflam is associated with a risk of serious, rare skin conditions, such as Stevens-Johnson syndrome. Additionally, common adverse events reported in clinical trials include less severe reactions like rash and pruritus (itching).

Q: What happens if I stop taking Meloflam suddenly after several months?

A: Since Meloflam is not an addictive medication, official information does not suggest that a withdrawal syndrome will occur upon stopping it suddenly. However, the symptoms of the underlying condition being treated, such as pain and inflammation, may return.

Q: Does Meloflam help with muscle soreness after exercise?

A: Meloflam’s formal indications are for specific inflammatory diseases like arthritis. Although it has pain-relieving properties, its primary regulatory use is centered on treating chronic inflammatory conditions, not general muscle soreness from exercise.

Q: Is it okay to drink alcohol while taking Meloflam?

A: Regulatory documents do not specifically prohibit alcohol consumption. However, alcohol use is generally discouraged when taking Meloflam, as both substances carry risks for gastrointestinal bleeding and liver toxicity, which could be additive.

Q: Are there generic versions of Meloflam available?

A: Yes, Meloflam's active ingredient, Meloxicam, is widely available as a generic medication.

Q: Can Meloflam cause water retention or swelling in the feet/ankles?

A: Yes, Meloflam may cause the development of new or worsening fluid retention, known as edema, which can manifest as swelling in the feet and ankles. It should be used with caution in individuals prone to fluid retention.

Q: Can Meloflam interfere with the effectiveness of birth control pills?

A: Official information indicates that Meloflam does not directly interfere with the effectiveness of common hormonal contraceptives. However, an interaction has been noted with specific types of oral contraceptives that contain drospirenone, where Meloflam may increase the risk of elevated potassium levels.

Q: Can Meloflam cause difficulty sleeping?

A: Difficulty sleeping, or insomnia, has been reported in clinical trial data as a possible, though uncommon, adverse reaction to Meloflam.

Q: Is there a risk of high blood pressure with Meloflam?

A: Yes, regulatory information warns that Meloflam may cause new onset of hypertension (high blood pressure) or worsen pre-existing high blood pressure. Patients taking this medication should have their blood pressure regularly monitored.

How should Meloflam be stored and disposed of?

Meloxicam tablets must be stored according to official regulatory requirements to ensure stability and potency.

Storage Requirements

Condition Regulatory Requirement
Temperature Store at Controlled Room Temperature: 20 C to 25 C (68 F to 77 F)
Protection Keep in a dry place, away from excessive heat, moisture, and direct light. Keep from freezing.
Container Dispense and store in a tightly closed container.
Child Safety Keep the medicine out of the sight and reach of children.

Disposal Instructions

Unused or expired Meloxicam should be disposed of via a drug take-back program if available. If no take-back program is readily accessible, the medication can be discarded in the household trash. The official procedure requires mixing the medicine with an undesirable substance, such as coffee grounds or cat litter, before placing the mixture in a sealed container and throwing it away. Scratch out all personal information on the packaging prior to disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Meloflam found in:

A-Z Index: